biotech.today

Details

  • ●Modalities: AAV gene therapy
  • ●Therapeutic areas: ophthalmology, neurology, rare disease
  • ●Key targets:
  • ●Indications: Undisclosed
  • ●Funding: $2B

Partners & investors

  • Novartis· Investor
  • Roche· Investor

Key considerations

  • ●AI tools in use: CapsidMap Platform
  • ●$100M Series A (2020)
  • ●Roche, Novartis, Sarepta, Astellas partnerships totaling $2B+ biobucks
Get live updates on Dyno Therapeutics’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Eric Kelsic

Co-Founder & CEO

capsid-engineeringml-drug-discovery
Visit website →LinkedIn →